These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39094523)

  • 1. Non-coding RNAs in Parkinson's disease: Regulating SNCA and alpha-synuclein aggregation.
    Thangavelu L; Moglad E; Afzal M; Almalki WH; Malathi H; Bansal P; Rani B; Walia C; Sivaprasad GV; Rajput P; Imran M
    Pathol Res Pract; 2024 Sep; 261():155511. PubMed ID: 39094523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p/alpha-synuclein axis in Parkinson's disease.
    Zhang J; Yang Y; Zhou C; Zhu R; Xiao X; Zhou B; Wan D
    Bioengineered; 2022 Feb; 13(2):4493-4516. PubMed ID: 35137671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanistic view of non-coding RNAs as a regulator of inflammatory pathogenesis of Parkinson's disease.
    Li Y; Yu C; Jiang X; Fu J; Sun N; Zhang D
    Pathol Res Pract; 2024 Jun; 258():155349. PubMed ID: 38772115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of non-coding RNAs in Parkinson's disease.
    Majidinia M; Mihanfar A; Rahbarghazi R; Nourazarian A; Bagca B; Avci ÇB
    Mol Biol Rep; 2016 Nov; 43(11):1193-1204. PubMed ID: 27492082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microarray analysis of an synthetic α-synuclein induced cellular model reveals the expression profile of long non-coding RNA in Parkinson's disease.
    Lin D; Liang Y; Jing X; Chen Y; Lei M; Zeng Z; Zhou T; Wu X; Peng S; Zheng D; Huang K; Yang L; Xiao S; Liu J; Tao E
    Brain Res; 2018 Jan; 1678():384-396. PubMed ID: 29137975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein-Induced Destabilized BMAL1 mRNA Leads to Circadian Rhythm Disruption in Parkinson's Disease.
    Liu JY; Xue J; Wang F; Wang YL; Dong WL
    Neurotox Res; 2023 Apr; 41(2):177-186. PubMed ID: 36662411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease.
    Emelyanov A; Kulabukhova D; Garaeva L; Senkevich K; Verbitskaya E; Nikolaev M; Andoskin P; Kopytova A; Milyukhina I; Yakimovskii A; Timofeeva A; Prakhova L; Ilves A; Vlasova I; Pchelina S
    J Neurol Sci; 2018 Dec; 395():135-140. PubMed ID: 30316070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.
    Tagliafierro L; Glenn OC; Zamora ME; Beach TG; Woltjer RL; Lutz MW; Chiba-Falek O
    Alzheimers Dement; 2017 Nov; 13(11):1237-1250. PubMed ID: 28431219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells.
    Chen Y; Lian YJ; Ma YQ; Wu CJ; Zheng YK; Xie NC
    Neurotoxicology; 2018 Sep; 68():212-221. PubMed ID: 29217406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
    McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
    Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.
    Guhathakurta S; Bok E; Evangelista BA; Kim YS
    Prog Neurobiol; 2017 Jul; 154():21-36. PubMed ID: 28445713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.
    Kong Y; Liang X; Liu L; Zhang D; Wan C; Gan Z; Yuan L
    PLoS One; 2015; 10(9):e0137432. PubMed ID: 26361355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.
    Schmitt I; Wüllner U; van Rooyen JP; Khazneh H; Becker J; Volk A; Kubisch C; Becker T; Kostic VS; Klein C; Ramirez A
    Eur J Hum Genet; 2012 Dec; 20(12):1265-9. PubMed ID: 22617348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease.
    Rezaei O; Nateghinia S; Estiar MA; Taheri M; Ghafouri-Fard S
    Eur J Pharmacol; 2021 Apr; 896():173914. PubMed ID: 33508286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32.
    Pavlou MAS; Colombo N; Fuertes-Alvarez S; Nicklas S; Cano LG; Marín MC; Goncalves J; Schwamborn JC
    Mol Neurobiol; 2017 Aug; 54(6):4257-4270. PubMed ID: 27339877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA.
    Zhang P; Park HJ; Zhang J; Junn E; Andrews RJ; Velagapudi SP; Abegg D; Vishnu K; Costales MG; Childs-Disney JL; Adibekian A; Moss WN; Mouradian MM; Disney MD
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1457-1467. PubMed ID: 31900363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
    Zhang QS; Wang ZH; Zhang JL; Duan YL; Li GF; Zheng DL
    Biomed Pharmacother; 2016 Oct; 83():153-159. PubMed ID: 27470562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.